clinical-gastroentrology-2016_scientifictracks-abstracts

5 / 13

Notes:
Page 28
Clinical Gastroenterology 2016
October 03-05, 2016
Volume 6, Issue 6(Suppl) J Gastrointest Dig Syst
ISSN:2161-069X JGDS, an open access journal
conferenceseries .com
October 03-05, 2016 Toronto, Canada
8th International Conference on
Clinical Gastroenterology & Hepatology
Zubair A khan, J Gastrointest Dig Syst 2016, 6:6(Suppl)
New therapies for GI cancer under the track gastrointestinal oncology
Zubair A khan
GI & LIVER Clinic Doost Medical Complex Multan, Pakistan
New treatments are emerging in field of gastroenterology oncology and it includes advancements in gastroesophageal
colorectal, pancreatic and anal canal carcinomas. FDA has approved angiogenesis inhibitor ramuciromab in unresectable,
advanced or metastatic gastric and gastroesophageal junction tumors after therapy with fluoropyrimidines and platinum
drugs. Trastuzumab is approved for locally advanced and metastatic HER-2neu positive gastroesophageal cancer only and
PD-1 inhibitor, pembrolizumab, in heavily pre-treated patients with metastatic gastric cancer. The major findings were that
it is feasible. In terms of toxicity, it is feasible with pembrolizumab to achieve a decrease in tumor size. Adjuvant imatinib
has become a standard treatment in all patients with significant risk for recurrence after resection of primary GISTs. FDA
also approved erlotinib hydrochloride in combination with gemcitabine for the treatment of patients with locally advanced,
unresectable or metastatic pancreatic carcinoma. In colon cancer, the antiangiogenic agent bevacizumab is approved in
combination with other agents. EGFR-1 (epidermal growth factor receptor 1) signaling pathway is thought to play a pivotal
role in tumor growth and progress of colorectal cancer. Cetuximab targets an epidermal growth factor receptor (EGFR), which
is found in about 80 percent of colorectal cancers and it’s effective in patients with NO K-ras mutation. Erbitux is effective even
if EGFR is not found in an individual tumor. In treatment of anal canal cancer traditionally treated with abdominoperineal
resection, resulting in high rates of morbidity and local recurrence. Pioneering work led to the finding that radiation therapy
(RT) combined with 5-fluorouracil (5-FU) and mitomycin results in high rates of local control and disease-free and colostomy-
free survival without surgery.
Biography
Zubair A khan has completed his MBBS from Nishter Medical College and Post-doctoral studies from Sheikh Zayed Hospital Lahore. Currently, he is working as a
Consultant Gastroenterologist at GI & LIVER Clinic Doost Medical Complex Multan, Pakistan. He has published more than 15 papers in reputed journals.